Posted by Michael Wonder on 13 Apr 2023
SAB Biotherapeutics granted fast track designation from FDA for SAB-176 influenza immunotherapy with high cross-reactivity to multiple strains of influenza
13 April 2023 - FDA greenlights advancement of SAB-176 Phase 2b trial and manufacturing approach to address influenza strain change.
SAB Biotherapeutics announced today that the US FDA has granted Fast Track designation for SAB-176, an investigational therapeutic for type A and type B influenza illness in high-risk patients, including those who have anti-viral resistant strains.
